{
    "nct_id": "NCT03509012",
    "official_title": "A Phase I Multicenter Study of Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)",
    "inclusion_criteria": "Inclusion criteria:\n\n* World Health Organization (WHO)/ECOG performance status of 0 or 1\n* Body weight >30 kg at enrollment and treatment assignment\n* At least 1 measurable lesion, not previously irradiated\n* No prior exposure to immune-mediated therapy (including therapeutic anticancer vaccines)\n* For patients with oropharyngeal HNSCC HPV status has to be known\n\nExclusion criteria:\n\n* Patients with simultaneous primary malignancies or bilateral tumors\n* Active or prior documented autoimmune or inflammatory disorders\n* Brain metastases or spinal cord compression\n* Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV; positive HIV 1/2 antibodies)\n* Has a paraneoplastic syndrome (PNS) of autoimmune nature\n* HNSCC cohort: Head and neck cancer that does not include unresectable, locally advanced cancer of oral cavity, larynx, oropharynx or hypopharynx. HNSCC of unknown primary are also excluded\n* NSCLC and SCLC cohort: Mixed SCLC and NSCLC histology\n* SCLC cohort: Extensive-stage SCLC\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 110 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}